logo
Plus   Neg
Share
Email

Frontier IP: Exscientia To Get Up To €240 Mln In AI-based Drug Deal With Bayer

Frontier IP Group Plc announced Friday that Artificial Intelligence- driven drug discovery company Exscientia has entered into a collaboration with Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) focused on cardiovascular disease and oncology.

Under the deal terms, Exscientia will initially work on three projects with targets agreed between both parties.

Exscientia may be eligible to receive up to 240 million euros including upfront and research payments, and for meeting near term and clinical milestones. The company may also receive sales royalties.

Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development said, "We are driving forward digital transformation in R&D as we believe that digital technologies such as AI can simplify and speed up the discovery and development of new drugs for patients. The collaboration with Exscientia is expected to help us to achieve project milestones earlier and at the same time accelerate timelines by enabling more precise identification of suitable drug targets and lead structures."

Exscientia's other partnerships include collaborations with Celgene, GSK, Roche, Sanofi, GT Apeiron, Rallybio and Evotec.

Frontier IP currently holds a 3.25 percent stake in the company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Tesla said it will produce ventilators at its Gigafactory in Buffalo, New York to support the city's hospitals amid the coronavirus pandemic. New York is the worst affected state in the U.S. Last Saturday, Musk tweeted that he "had a long engineering discussion with Medtronic about state-of-the-art ventilators. Luxury fashion house Ralph Lauren will donate $10 million to help fight the coronavirus pandemic and manufacture face masks as well as medical gowns in the U.S. The company's charity arm, the Ralph Lauren Corporate Foundation, said in a statement that it is committing $10 million towards the global response to the COVID-19 pandemic. General Motors Co. is delaying work on new vehicle models and is cutting pay for its executives as part of efforts to conserve cash amid the coronavirus or Covid-19 pandemic. The automotive giant also extended the shutdown of North American plants indefinitely. Multiple reports cited an internal memo that salaried workforce will have 20 percent of pay deferred starting April 1.
Follow RTT
>